These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12871683)

  • 21. Nicorandil associated anal ulceration.
    Watson A; Suttie S; Fraser A; O'Kelly T; Loudon M
    Colorectal Dis; 2004 Sep; 6(5):330-1. PubMed ID: 15335365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris.
    Hata N; Takano M; Kunimi T; Kishida H; Takano T
    Int J Clin Pharmacol Res; 2001; 21(1):59-63. PubMed ID: 11708575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management.
    IONA Study Group
    Heart; 2001 Jun; 85(6):E9. PubMed ID: 11359763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nicorandil for angina.
    Drug Ther Bull; 1995 Dec; 33(12):89-92. PubMed ID: 8777891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of nicorandil in angina: subgroup analyses.
    IONA Study Group
    Heart; 2004 Dec; 90(12):1427-30. PubMed ID: 15547020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon: A Randomized Clinical Trial.
    Sani HD; Eshraghi A; Nezafati MH; Vojdanparast M; Shahri B; Nezafati P
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):401-6. PubMed ID: 25701829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of the impact of nicorandil in angina (IONA) trial.
    Walker A; McMurray J; Stewart S; Berger W; McMahon AD; Dargie H; Fox K; Hillis S; Henderson NJ; Ford I
    Heart; 2006 May; 92(5):619-24. PubMed ID: 16614274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.
    Frampton J; Buckley MM; Fitton A
    Drugs; 1992 Oct; 44(4):625-55. PubMed ID: 1281076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Yamada S; Kasuga H; Ichimiya S; Kanashiro M; Mitsuhashi H; Maruyama S; Matsuo S; Naruse K; Matsubara T; Murohara T
    Clin Ther; 2007 Jan; 29(1):110-22. PubMed ID: 17379051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determinants of coronary events in patients with stable angina: results from the impact of nicorandil in angina study.
    IONA Study Group
    Am Heart J; 2005 Oct; 150(4):689. PubMed ID: 16209965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil.
    Matsuo H; Watanabe S; Segawa T; Yasuda S; Hirose T; Iwama M; Tanaka S; Yamaki T; Matsuno Y; Tomita M; Minatoguchi S; Fujiwara H
    Eur Heart J; 2003 Jul; 24(14):1296-303. PubMed ID: 12871686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colonic and parastomal ulceration related to nicorandil.
    Payne CJ; Whitelaw SC
    Surg Laparosc Endosc Percutan Tech; 2011 Jun; 21(3):e132-3. PubMed ID: 21654285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study.
    Meeter K; Kelder JC; Tijssen JG; Bucx JJ; Henneman JA; Kerker JP; Hugenholtz PG
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S59-66. PubMed ID: 1282178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy.
    Krumenacker M; Roland E
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S93-102. PubMed ID: 1282184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of low dose denopamine, a beta1-adrenoceptor agonist, in a patient with vasospastic angina refractory to intensive medical treatment.
    Nakajima D; Negoro N; Nakaboh A; Nakakoji T; Hoshiga M; Nariyama J; Ishihara T; Hanafusa T
    Int J Cardiol; 2006 Apr; 108(2):281-3. PubMed ID: 15913812
    [No Abstract]   [Full Text] [Related]  

  • 36. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and meta-analysis of the literature.
    Luo B; Wu P; Bu T; Zeng Z; Lu D
    Int J Cardiol; 2014 Oct; 176(3):661-9. PubMed ID: 25217220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of nicorandil therapy in ischemic myocardial injury by using contrast-enhanced and functional MR imaging.
    Lund GK; Higgins CB; Wendland MF; Watzinger N; Weinmann HJ; Saeed M
    Radiology; 2001 Dec; 221(3):676-82. PubMed ID: 11719662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertrophic obstructive cardiomyopathy with multiple coronary arteries to right ventricular microfistulas: a case report and review of the literature.
    Meena DS; Meena CB; Parvez J
    J Med Case Rep; 2017 Jan; 11(1):24. PubMed ID: 28143616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Update on the treatment with nitrates in ischemic cardiopathy].
    Lanza GA; Maseri A
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):187-90. PubMed ID: 12497905
    [No Abstract]   [Full Text] [Related]  

  • 40. A symposium: A new treatment for angina pectoris and heart failure. October 17, 1987, San Francisco. Proceedings.
    Am J Cardiol; 1989 Jun; 63(21):1J-85J. PubMed ID: 2525318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.